Substituted 2-(benzyloxy)pyrimidine Inhibitors for PD-1/PD-L1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using PD-1/PD-L1 antibodies face adverse effects such as fatigue, rash, diarrhea, and immune-related adverse events due to their long residence time, highlighting the need for potent and selective small molecule inhibitors that can provide increased oral bioavailability and controlled treatment.
Innovation Solution
Development of substituted 2-(benzyloxy)pyrimidine compounds that inhibit PD-1/PD-L1 activation, offering a chemical moiety for cancer treatment with potential as small molecule inhibitors, capable of up-regulating the immune system to combat cancer effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 antibodies are used for cancer treatment, then immune responses against cancer cells are enhanced, but adverse effects such as fatigue, rash, diarrhea, and immune-related adverse events occur due to long residence time
Solution Approach 1:
The patent changes the molecular parameter from large antibody molecules to small molecule inhibitors with specific chemical structures (substituted 2-(benzyloxy)pyrimidine compounds). This parameter change reduces residence time in the body while maintaining PD-1/PD-L1 pathway inhibition, thereby reducing adverse effects like fatigue, rash, and diarrhea while preserving cancer treatment efficacy
Solution Approach 2:
The invention employs short-acting small molecule inhibitors instead of long-residence antibodies. These small molecules act as temporary, controllable inhibitors that can be metabolized and eliminated more quickly, providing a way to stop treatment effects faster if adverse events occur, thus reducing the burden of long-term adverse effects
2Reliability
If antibodies are used for PD-1/PD-L1 inhibition, then immune system is up-regulated to combat cancer, but oral bioavailability is limited and treatment control is reduced
Solution Approach 1:
The patent substitutes the mechanical/administrative complexity of antibody delivery (intravenous infusion, cold chain storage, long half-life) with small molecule chemistry that enables oral administration. The small molecule compounds can be taken orally with better bioavailability, stored at room temperature, and have shorter half-lives for better treatment control
Solution Approach 2:
The invention changes the pharmacokinetic parameters by using small molecules with improved oral absorption, metabolism, and elimination profiles compared to antibodies. This allows for flexible dosing regimens and better treatment control while maintaining immune system up-regulation for cancer combat
Data Source
AI summary
The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.